Share this to:

Support & Insight for the Autumn of Life

Namenda’s Switch to Namenda-XR

VIDEO & ARTICLE:

Namenda® is the most popular drug for mid-stage Alzheimer’s. The manufacturer is discontinuing Namenda and replacing it with extended-release Namenda-XR. CBS wants to know, is this switch about health or money?


Namenda® for Alzheimer’s is a popular medication that will be going generic in the near future. The new generic formulation, known as Memantine, will offer the same benefits at a much lower cost.

Now, the manufacturer of regular Namenda has announced they will be switching everyone using the medication to the patented, extended release version known as
Namenda-XR®. They plan to do so about six months before generic Memantine hits your pharmacist’s shelves.

Continued below video…

On the one hand, the extended release Namenda-XR has advantages over regular Namenda. With regular Namenda, one has to remember to take it twice a day, while Namenda-XR is a once-a-day formulation. Furthermore, the slow, steady supply of medication that comes from extended-release drugs tends to have fewer, milder side effects.

On the other hand, these may be small advantages at a big cost. Namenda-XR will not go generic for years to come. That means the big savings from generic Memantine may elude those forced to switch to full-priced extended-release Namenda-XR.

In other words, you may currently be perfectly happy with regular Namenda. Had this switch not occurred, you may have decided to make the easy switch from regular Namenda to regular Memantine to save money. After all, they are the same thing; Memantine just costs less. But once you are forced to switch to extended-release Namenda-XR, chances are you will think twice before switching to regular Memantine. People are often resistant to switching from a brand-name drug to a generic when it is not exactly the same thing.

So keep your eye out for the upcoming availability of the generic form of Namenda called “Memantine”. When it becomes available, talk to your doctor about it. Though switching to the lower-cost generic formulation just got complicated, a small education about what’s going on here may be all it takes to save a big bundle.

SOURCE:
CBS Evening News
Subscribe
Notify of
guest

2 Comments
Inline Feedbacks
View all comments
outandabout
outandabout
8 years ago

My husband was switched to Namenda XR several months ago. Now when it's time to renew the prescription, no one has it . . . .not mail order or the local pharmacies. What's going on?

Anonymous
Anonymous
Reply to  outandabout
8 years ago

I agree 100% We have been trying to refill our script for about three weeks now at various pharmacies to no avail. Since no one really knows of any absolute positive affects from using Namenda, the manufacturer may discover a large loss in sales once thousands of patients acknowledge the ineffectiveness of this drug and opt out. What is presented is fear of what might happen if you do not take this medication. A real crap shoot with big bucks involved.

B. Berger

B. Berger

Visit Our Pages On:

Welcome

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Related

news-resveratol.jpeg
Green Tea, Cocoa & Red Wine Reduce Beta Amyloid Plaques
130915-donepezil.jpeg
Cognitive Boost for Dementia with Lewy Bodies
160614-k.jpeg
Alzheimer's Misdiagnosis # 5: Lyme Disease

Books

Amazon Books
2
0
Would love your thoughts, please comment.x
()
x
News to Get at the Truth

Subscribe To Our Weekly Newsletter

Enjoy thought-provoking videos & articles
News to Get at the Truth

Subscribe To Our Weekly Newsletter